![Thomas Dyrberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Dyrberg
Direktor/Vorstandsmitglied bei
Lux Biosciences, Inc.
Profil
Thomas Dyrberg is currently a Director at Lux Biosciences, Inc., Kanyos Bio, Inc., Nuvelution Pharma, Inc., and Theia, Inc. He is also a Senior Advisor at Novo Holdings AS (Denmark) and a Managing Partner at Novo Ventures 1 A. Previously, he served as the Chief Executive Officer at Novo Nordisk Fonden and the Deputy Chairman at Veloxis Pharmaceuticals A. He has also held positions as Chairman at Hemofocus ApS, Director at Sapphire Therapeutics, Inc., Director at Gloucester Pharmaceuticals, Inc., Director at BioMimetic Therapeutics, Inc., Independent Director at Galera Therapeutics, Inc., Independent Director at IVERIC bio, Inc., Director at AlloCure, Inc., Director at Cell Medica Switzerland AG, Director at PanOptica, Inc., Director at Imagen Biotech, Inc., and Independent Director at Entasis Therapeutics, Inc. Additionally, he worked as a Manager-International Clinical Project at Novo Nordisk A and as a Principal at The Scripps Research Institute.
Dr. Dyrberg holds a doctorate degree from the University of Copenhagen, conferred in 1986 and 1981.
Aktive Positionen von Thomas Dyrberg
| Unternehmen | Position | Beginn |
|---|---|---|
Lux Biosciences, Inc.
 Lux Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines to treat ophthalmic diseases | Direktor/Vorstandsmitglied | - |
Theia, Inc. | Direktor/Vorstandsmitglied | - |
Novo Holdings A/S (Denmark)
 Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager | Corporate Officer/Principal | - |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Thomas Dyrberg
| Unternehmen | Position | Ende |
|---|---|---|
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures invests in companies located in Europe, the United States and Asia. The firm targets companies operating in the fields of health technology, health services, biotechnology and medical specialties sectors. It provides financing for early stage capital requirements. | Private Equity Investor | 01.12.2025 |
| PRAXIS PRECISION MEDICINES, INC. | Direktor/Vorstandsmitglied | 01.10.2020 |
| GALERA T COM USD0. | Direktor/Vorstandsmitglied | 06.11.2019 |
| IVERIC BIO, INC. | Direktor/Vorstandsmitglied | 15.05.2019 |
| VELOXIS PHARMACEUTICALS A/S | Direktor/Vorstandsmitglied | 28.07.2016 |
Ausbildung von Thomas Dyrberg
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
78
Beziehungen ersten Grades
24
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 24 |
|---|---|
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Sapphire Therapeutics, Inc.
 Sapphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
Gloucester Pharmaceuticals, Inc.
 Gloucester Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops products for the treatment of cancer patients | Health Technology |
BioMimetic Therapeutics, Inc.
 BioMimetic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and sells protein therapeutics for tissue and organ regeneration | Health Technology |
Lux Biosciences, Inc.
Lux Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines to treat ophthalmic diseases | Health Technology |
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for the prevention of organ rejection in kidney transplant patients | Health Technology |
Galera Therapeutics, Inc.
 Galera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs to reduce normal tissue toxicity from radiotherapy | Health Technology |
Novo Nordisk Fonden
 Novo Nordisk Fonden Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation | Miscellaneous |
Novo Holdings A/S (Denmark)
Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager | Finance |
The Scripps Research Institute
 The Scripps Research Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Copenhagen
 University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IVERIC bio, Inc.
 IVERIC bio, Inc. BiotechnologyHealth Technology Operates as a science-driven biopharmaceutical company that develops novel treatments for retinal diseases | Health Technology |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures invests in companies located in Europe, the United States and Asia. The firm targets companies operating in the fields of health technology, health services, biotechnology and medical specialties sectors. It provides financing for early stage capital requirements. | Finance |
AlloCure, Inc.
 AlloCure, Inc. BiotechnologyHealth Technology Develops cell therapies for the treatment of kidney diseases, organ transplants and multi-organ injuries | Health Technology |
Hemofocus ApS
 Hemofocus ApS Medical SpecialtiesHealth Technology Provides anticoagulant products | Health Technology |
Cell Medica Switzerland AG
 Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Researches, develops, manufactures, and distributes pharmaceutical, biological, medical, and diagnostic products | Health Technology |
PanOptica, Inc.
 PanOptica, Inc. Pharmaceuticals: MajorHealth Technology Manufactures ophthalmology drugs for treatment of eye diseases | Health Technology |
Imagen Biotech, Inc.
 Imagen Biotech, Inc. BiotechnologyHealth Technology Develops therapeutics for blinding diseases | Health Technology |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Health Technology |
Nuvelution Pharma, Inc.
 Nuvelution Pharma, Inc. BiotechnologyHealth Technology Provides solutions for R&D companies in the pharmaceutical and biotech industries | Health Technology |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for infectious diseases | Health Technology |
Theia, Inc. | |
Praxis Precision Medicines, Inc.
 Praxis Precision Medicines, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company which develops therapies for central nervous system disorders | Health Technology |
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical biopharmaceutical company that engages in development of antibacterial products | Commercial Services |
